Julia Rotow, MD
Dana Farber Cancer Institute
Topic Presenter
Financial Disclosure
AbbVie, Amgen, AstraZeneca, BioAtla, BioNTech, Blossom Hill, Bristol Myers Squibb, Boehringer Ingelheim, Caris, Catalyst, Daiichi Sankyo, Genentech, Gilead, G1 Therapeutics, Guardant Health, Johnson & Johnson, Jazz Pharmaceuticals, Merus, Novocure, Nuvalent, Nuvation Bio, Ottimo, Pfizer, Regeneron, Sanofi-Genzyme, Summit Therapeutics, and Takeda.
Consultant
Contracted for research (institutional) with AbbVie, Altor Bioscience, AstraZeneca, Bicycle Therapeutics, BioAtla, BioNTech, Black Diamond, Blossom Hill, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo, Duality, Enliven Therapeutics, EpimAb, Immunity Bio, LOXO Oncology, Nuvalent, ORIC Pharmaceuticals, RedCloud Bio, Regeneron Summit, Synthekine
Grant Or Contract
Honoraria from AstraZeneca, Daiichi Sankyo, Johnson & Johnson, and Pfizer.
Other